A trend towards reduced AML burden was seen at an intermediate level of CKS1B expression (AML26), but CKS1 inhibition had no significant effect on bulk AML for patients with the lowest CKS1B expression (AML27 and AML32; Figure 1D). This evidence concerns the gene CKS1B and acute myeloid leukemia.